Asimov ^Investors

Asimov is an organization that specializes in using artificial intelligence to develop tools for the design and manufacture of next-generation therapeutics. Their multidisciplinary team integrates mammalian synthetic biology, computer-aided design, and machine learning to advance the field of biologics and gene therapies. Established in 2017 by Raja Srinivas in Boston, Massachusetts, Asimov provides an end-to-end platform for genetic design, including engineered GMP host cells, experimentally validated genetic parts, and cloud-based software for designing and optimizing genetic systems. Their achievements include the development of highly characterized GMP host cells for therapeutic applications and the creation of over 1000 experimentally validated genetic parts to control cell biology.